Today: 21 June 2026
Unilever share price slips on Alicorp deal: what ULVR investors are watching next
29 January 2026
2 mins read

Unilever share price slips on Alicorp deal: what ULVR investors are watching next

London, January 29, 2026, 08:32 (GMT) — Regular session

  • Unilever shares edged down about 0.5% in early London trading
  • Company agreed to sell its Home Care business in Colombia and Ecuador to Alicorp, the Peruvian company
  • Investors are shifting focus to Unilever’s mid-February earnings, eager to spot any fresh moves in the company’s portfolio

Unilever’s shares dipped in early London trading Thursday after the company sold its home care business in Colombia and Ecuador to Peruvian rival Alicorp. By 08:32 GMT, the stock was down 0.45% at 4,793.75 pence.

Investors want steady, reliable growth from major consumer staples companies—not just price increases and cost cuts. Unilever has talked more about “sharpening” its portfolio, and this deal represents another small step in that direction.

With no price disclosed, the market is left guessing the deal’s value. Attention now shifts to what other assets could be on the block and whether selling them genuinely boosts execution or just slices through the company’s layers.

Unilever revealed the sale covers local household and laundry brands like Fab, 3D, Aromatel, and Deja. The transaction still needs regulatory approval and must meet standard closing conditions. “It aligns with our ambition to sharpen our portfolio and focus on the categories where we can lead, innovate and grow sustainably,” said Reginaldo Ecclissato, President of Unilever Markets. Unilever

Alicorp called the transaction an asset purchase. According to a filing with Peru’s securities regulator (SMV), its subsidiaries in Colombia and Ecuador have inked agreements to buy 100% of Unilever’s home care business assets in those countries. The deal awaits regulatory approval in both markets. No financial terms or timelines were disclosed.

Unilever’s team in Ecuador insisted business will proceed normally. Marcos Dueñas, general manager of Unilever Ecuador, said the decision followed a portfolio review. “Alicorp knows the category well,” he told the local news outlet Primicias. The transition won’t affect operations. Primicias

An adviser on the transaction shared a similar perspective. Inverlink, acting as Unilever’s financial adviser for the sale, described the move as consistent with Unilever’s strategy to concentrate on its core “power brands.” They also noted the deal is expected to accelerate Alicorp’s expansion throughout the Andean region. El Universo

Home care, which includes detergents, cleaners, and laundry products, continues to be a fiercely contested sector. Unilever is up against heavyweight rivals such as Procter & Gamble and Reckitt, plus strong local contenders. Smaller, country-specific portfolios may generate profits, but they tend to sap management focus and marketing budgets.

The deal awaits regulatory approval, with authorities able to prolong the review or attach conditions in critical areas. Since terms remain undisclosed, investors are left guessing the proceeds and whether this sale signals a simple exit or part of a larger strategic reshuffle.

Unilever’s Q4 and full-year 2025 results are due Feb. 12, marking the next key date. Investors will watch closely for news on disposals, reinvestment strategies, and the 2026 demand outlook. The company is also lined up to speak at the CAGNY Conference on Feb. 17.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Micron Surpasses $1,000 Amid AI-Driven Memory Demand Surge
    June 21, 2026, 9:42 AM EDT. Micron Technology's shares surged past $1,000, joining the trillion-dollar club as AI reshapes the semiconductor sector. The rally is fueled by robust demand for high-bandwidth memory (HBM) and advanced DRAM, essential for AI workloads. Micron's entire 2026 HBM production is sold out, with supply shortages expected through 2027 amid escalating AI investments. Market research forecasts the global memory market reaching $1.3 trillion by 2027, with DRAM revenue tripling this year. Despite a high price-to-earnings ratio of 48, Micron's valuation reflects strong earnings growth amid a historically volatile memory market. Investors are watching AI-driven demand sustainability and pricing power to gauge the stock's trajectory.

Latest articles

SpaceX Stock Risks Build as ARK ETF Flows, Retail Rules and Lockups Test IPO Rally

SpaceX Stock Risks Build as ARK ETF Flows, Retail Rules and Lockups Test IPO Rally

21 June 2026
SpaceX ended its first public week at $185, up 37% from its $135 IPO price but down from Tuesday’s $225.64 high, as index inclusion and ETF flows drive demand while looming lock-up releases and the first earnings report threaten new supply and volatility, with Moody’s, Fitch, and S&P giving investment-grade ratings but skeptics warning on valuation.
Germany faces pension reform tussle as costs for ageing, defence rise

Germany faces pension reform tussle as costs for ageing, defence rise

21 June 2026
Germany’s pension commission will propose raising the retirement age to 68 by 2051 and creating a state-run investment fund, forcing Chancellor Merz’s coalition to weigh later retirement, higher contributions, and market risk as Germany’s aging population strains public finances, Reuters and Handelsblatt report.
AbbVie-Apogee deal on radar for US healthcare stocks next week

AbbVie-Apogee deal on radar for US healthcare stocks next week

21 June 2026
AbbVie is reportedly nearing a $10.9 billion cash takeover of Apogee Therapeutics, offering a roughly 60% premium to Apogee’s Thursday close, with an announcement possible Monday; the deal puts both stocks at the center of Monday’s healthcare sector trading after a weak week for XLV, while risks remain as talks are unconfirmed and Apogee’s lead drug has not entered Phase 3 trials.
HSBC share price slips from record highs as investors weigh Fed pause and Hang Seng move
Previous Story

HSBC share price slips from record highs as investors weigh Fed pause and Hang Seng move

Babcock share price today: BAB slips after fresh buyback filing, March year-end in focus
Next Story

Babcock share price today: BAB slips after fresh buyback filing, March year-end in focus

Go toTop